Business Context and Reporting Period
This Form 6-K filing covers the month of September 2011 for Prana Biotechnology Limited (ASX: PBT), a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding the issuance of securities without prior disclosure to investors.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific capital event.
- Securities Issued: 196,000 Ordinary Fully Paid Shares
- Issue Date: September 19, 2011
- Total Issue Value: AUD$ 35,579
- Implied Price Per Share: Approximately AUD$ 0.1815
Material Changes
The primary material change reported is the increase in the company's share capital through the issuance of 196,000 new ordinary shares. The company has applied to the Australian Securities Exchange (ASX) for quotation of these shares. No comparative financial data or prior period changes are disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a regulatory compliance notice confirming that the company has complied with Chapter 2M and Section 674 of the Corporations Act regarding the issuance.
Investor Verification Checklist
- Verify the exact number of shares issued (196,000) and the total consideration received (AUD$ 35,579).
- Confirm the current status of the ASX quotation application for these newly issued shares.
- Review the company's latest Form 20-F or annual report for comprehensive financial statements, as this 6-K does not contain them.
- Check for any subsequent filings regarding the use of proceeds from this specific issuance.